Morpholine Salicylate

Morpholine Salicylate

SCHEMBL24540

O=C(ON1CCOCC1)c1ccccc1O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.59
NPC1 O15118 2/20 0.59
MGLL Q99685 1/20 0.53
BCHE P06276 1/20 0.51
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
ALOX15 P16050 1/20 0.45
TDP1 Q9NUW8 2/20 0.44
GAA P10253 2/20 0.43
KDM1A O60341 1/20 0.43
KMT2A Q03164 1/20 0.43
MAOB P27338 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5874810 0.83 NPC1 (0.55) RAB9ANPC1LMNATSHRHPGD
SCHEMBL27640541 0.83 PKM (0.59) RAB9ANPC1LMNAHPGDKMT2A
SCHEMBL10594875 0.82 MAPT (0.49) RAB9ANPC1LMNATSHRHPGD
SCHEMBL28702972 0.81 TSHR (0.47) RAB9ANPC1BCHELMNATSHR
SCHEMBL5875374 0.81 TSHR (0.47) RAB9ANPC1BCHELMNATSHR
SCHEMBL27579023 0.80 RAB9A (0.47) RAB9ANPC1LMNATSHRGAA
SCHEMBL226315 0.78 KMT2A (0.55) NPC1LMNATSHRHPGDGAA
SCHEMBL27551530 0.77 KMT2A (0.66) RAB9ANPC1TSHRTDP1GAA
Ammonia Solution, Strong SCHEMBL11880905 0.77 KMT2A (0.54) NPC1LMNATSHRHPGDGAA
SCHEMBL1665838 0.77 TSHR (0.43) RAB9ANPC1LMNATSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2046 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255781-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-08-14 US claimed
US-12296043-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2025-05-13 US claimed
EP-4510999-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS Bristol-Myers Squibb Company (US) 2025-02-26 EP claimed
US-20240165020-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-05-23 US claimed
EP-4360653-A2 LIQUISOFT CAPSULES Patheon Softgels Inc. (US) 2024-05-01 EP claimed
US-20240041935-A1 PREVENTION AND TREATMENT OF REPRODUCTIVE FAILURE BY REGENERATIVE CELLS AND ADJUVANTS CREATIVE MEDICAL TECHNOLOGIES, INC. (US) 2024-02-08 US claimed
US-11872307-B2 Liquisoft capsules PATHEON SOFTGELS INC. (US) 2024-01-16 US claimed
EP-3682872-B1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2024-01-03 EP claimed
WO-2023205619-A1 PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-10-26 WO claimed
US-20220211616-A1 LIQUISOFT CAPSULES PATHEON SOFTGELS INC (US) 2022-07-07 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0786999-A4 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO INC (US) 1999-01-20 EP claimed
WO-1998020864-A9 USE OF SELECTED NON-STEROIDAL ANTIINFLAMMATORY COMPOUNDS FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES 1998-08-27 WO claimed
WO-1998020864-A2 USE OF SELECTED NON-STEROIDAL ANTIINFLAMMATORY COMPOUNDS FOR THE PREVENTION AND THE TREATMENT OF NEURODEGENERATIVE DISEASES UNIVERSITA' DEGLI STUDI DI BRESCIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE (IT) 1998-05-22 WO claimed
EP-0786999-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-08-06 EP claimed
US-5543417-A 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent MERCK & CO., INC. (US) 1996-08-06 US claimed
WO-1996012487-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1996006544-A1 COMPOSITION FOR STRAIGHTENING AND PERMANENTLY WAVING KERATIN BASED MATERIALS VIRGINIA COMMONWEALTH UNIVERSITY (US) 1996-03-07 WO claimed